Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash equivalents and investments of $258.3 million, with an additional $23.7 million received from a favorable arbitration outcome [15][16] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, while the full year net loss was $189.9 million, or $0.87 per share [17][18] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [16][18] Business Line Data and Key Metrics Changes - The focus for 2026 is on delivering clinical milestones for two key programs: cema-cel in ALPHA3 and ALLO-329 in RESOLUTION [5][10] - ALPHA3 aims to redefine management of large B-cell lymphoma by testing early MRD-guided consolidation with allogeneic CAR T therapy [10][11] - ALLO-329 is designed for autoimmune diseases, with initial proof of concept data expected in June 2026 [12][14] Market Data and Key Metrics Changes - The company is expanding its clinical trials into community cancer centers, which have historically been excluded from offering CAR T therapies [11][12] - Over 60 active sites across the U.S. and Canada are involved in the ALPHA3 study, with plans for expansion into Australia and South Korea [11][12] Company Strategy and Development Direction - The company aims to validate its allogeneic platform as a scalable and accessible cell therapy option [5][8] - There is a focus on disciplined execution and prioritization of resources towards programs with the greatest potential [8][14] - The company is positioned to execute through critical proof points in 2026, with a cash runway extended into the first quarter of 2028 [8][18] Management's Comments on Operating Environment and Future Outlook - Management believes the cell therapy environment is shifting towards evidence-based outcomes, emphasizing data and disciplined execution [5][6] - The company is optimistic about the potential of its allogeneic CAR T therapies to expand access and improve patient outcomes [5][8] - Management is focused on generating data that clearly defines the role of allogeneic CAR T in oncology and autoimmune diseases [14][18] Other Important Information - The company has made prudent use of its ATM equity facility, raising an additional $20.7 million year to date [15][16] - Guidance for operating cash expenses in 2026 is expected to be approximately $150 million, with GAAP operating expenses around $210 million [18] Q&A Session Summary Question: Can you elaborate on the safety parameters for the ALPHA3 data update? - Management plans to provide high-level safety information, focusing on serious adverse events and outpatient delivery feasibility [22][23] Question: What read-throughs do you have from the recent ZUMA-7 MRD analysis? - Management views the ZUMA-7 study as consistent with their expectations for MRD clearance and its correlation to clinical outcomes [26][27] Question: What is the expected rate of spontaneous MRD conversion in the observation arm of ALPHA3? - Management has modeled a spontaneous clearance rate of about 20%, expecting 2-3 patients to potentially convert from MRD positive to negative [46][50] Question: How many community centers in the ALPHA3 study had prior CAR T or transplant capabilities? - Approximately 50% of the sites are community practices, with some being CAR T naive and successfully enrolling patients [62][63] Question: Will you present data on CD70 positive T cell depletion in ALLO-329? - Management indicated that translational data will be collected and analyzed, focusing on the 20 million cell dose level [68][70]

Core Insights - Allogene Therapeutics is at a critical juncture with the upcoming interim data from the ALPHA3 trial of cema-cel, which aims to determine if early, MRD-guided allogeneic CAR T therapy can prevent relapse in large B-cell lymphoma (LBCL) [2][3] - The company is focused on demonstrating that allogeneic CAR T can be delivered at a biologic-like scale, moving beyond academic settings [2][4] - Allogene has a cash runway extending into Q1 2028, allowing for disciplined execution and data delivery across its portfolio [2][13] Company Updates - The ALPHA3 trial is designed to evaluate cema-cel as a "7th cycle" of first-line therapy, integrating it without altering existing treatment workflows [4] - The trial is enrolling patients at over 60 clinical sites, including both academic and community cancer centers, to enhance patient access [4] - An interim futility analysis is scheduled for April 2026, which will compare MRD clearance rates between cema-cel and observation [5] Product Development - ALLO-329 is a next-generation allogeneic CAR T therapy targeting CD19/CD70, utilizing proprietary Dagger technology for built-in lymphodepletion [6][10] - The Phase 1 RESOLUTION trial for ALLO-329 is currently enrolling patients across multiple autoimmune indications, with proof-of-concept data expected in June 2026 [7][10] - ALLO-316 has shown significant response rates in metastatic solid tumors, with the TRAVERSE trial completed and the company exploring partnership opportunities [11] Financial Performance - As of December 31, 2025, Allogene reported $258.3 million in cash, cash equivalents, and investments, extending its cash runway into Q1 2028 [12][13] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [16] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, with a full-year net loss of $190.9 million, or $0.87 per share [16][22]

Core Insights - Allogene Therapeutics has achieved a favorable arbitration outcome with Servier regarding cemacabtagene ansegedleucel (cema-cel), reaffirming its full development and commercial control in the U.S., EU, and UK, while paving the way for global commercialization rights [1][5][8] Group 1: Arbitration Outcome - The tribunal rejected Cellectis's allegations against Servier regarding development obligations and financial claims, determining that milestone payments are contingent upon FDA acceptance of a Biologics License Application (BLA) [6] - A partial termination of the license was ordered, limited to the UCART19 V1 product, and Cellectis was directed to negotiate a direct license to Allogene if pursued [6] Group 2: Future Developments - Allogene is entering 2026 with improved fundamentals and is approaching a significant catalyst period in the allogeneic CAR T field, including an interim futility analysis in 1H 2026 for cema-cel in first-line patients with large B-cell lymphoma (LBCL) [2][5]

Core Insights - Allogene Therapeutics has achieved a favorable arbitration outcome with Servier regarding cemacabtagene ansegedleucel (cema-cel), reaffirming its full development and commercial control in the U.S., EU, and UK, while paving the way for global commercialization rights [1][5][8] Group 1: Arbitration Outcome - The tribunal rejected Cellectis's allegations against Servier regarding development obligations and financial claims, determining that milestone payments are contingent upon FDA acceptance of a Biologics License Application (BLA) [6] - A partial termination of the license was ordered, limited to the UCART19 V1 product, and Cellectis was directed to negotiate a direct license to Allogene on similar terms if pursued [6] Group 2: Future Developments - With the legal matter resolved, Allogene is entering 2026 with improved fundamentals and is approaching a significant catalyst period in the allogeneic CAR T field [2] - An interim futility analysis for cema-cel in first-line patients with large B-cell lymphoma (LBCL) is scheduled for the first half of 2026 [2][5] Group 3: Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T products for cancer and autoimmune diseases, aiming to provide readily available cell therapy on demand [3] - The company is led by a management team with extensive experience in cell therapy and is developing a pipeline of "off-the-shelf" CAR T cell product candidates [3]

Allogene Corporate Overview November 2025 Legal Disclaimers This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. To the extent that statements contained in this presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statem ...

Core Insights - Allogene Therapeutics is advancing its allogeneic CAR T therapy portfolio aimed at improving access to cell therapy for cancer and autoimmune diseases, with a focus on earlier treatment and broader application [1][2] Financial Performance - For Q3 2025, the company reported a net loss of $41.4 million, or $0.19 per share, with total operating expenses of $44.9 million [14][19] - As of September 30, 2025, Allogene had $277.1 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2027 [10][21] Clinical Trials and Developments - The pivotal Phase 2 ALPHA3 trial with cema-cel is exploring allogeneic CAR T therapy for earlier-line treatment of large B-cell lymphoma (LBCL), with over 50 clinical sites active in the U.S. and Canada, and additional sites expected to open in Australia and South Korea in early 2026 [3][6] - The next milestone for the ALPHA3 trial is a futility analysis expected in the first half of 2026, focusing on minimal residual disease (MRD) conversion rates [4][6] - The Phase 1 RESOLUTION trial with ALLO-329 is investigating a dual CD19/CD70 CAR for autoimmune diseases, with a focus on reducing or eliminating lymphodepletion to improve tolerability [5][7] - ALLO-316 is the only allogeneic CAR T therapy showing significant response rates in metastatic solid tumors, with the TRAVERSE trial in renal cell carcinoma demonstrating early signs of efficacy [8][6] Strategic Vision - The company aims to shift from personalized therapies to off-the-shelf treatments that can be more widely available, enhancing consistency, safety, and quality in cell therapy [2][12] - Allogene's approach leverages ex vivo manufacturing to improve the precision and control of cell products before administration to patients [2][12]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company had $335.5 million in cash, cash equivalents, and investments [29] - Research and development expenses for Q1 2025 were $50.2 million, including $5 million in non-cash stock-based compensation [29] - General and administrative expenses for Q1 2025 were $15 million, including $7.1 million in non-cash stock-based compensation [29] - The net loss for Q1 2025 was $59.7 million, or $0.28 per share, including $12.2 million in non-cash stock-based compensation [29] - Updated guidance for 2025 indicates an expected cash burn of approximately $150 million, with full-year GAAP operating expenses projected at approximately $230 million [29] Business Line Data and Key Metrics Changes - The ALPHA-three trial has seen over 250 patients consented for MRD screening, with nearly half in the last three months, indicating improved site engagement [9][20] - ALLO-three sixteen is showing signs of efficacy in heavily pretreated advanced renal cell carcinoma, with a 50% best overall response rate in patients expressing high levels of CD70 [24] - ALLO-three 29 is set to launch the RESOLUTION trial mid-2025, aiming to change treatment for autoimmune diseases by potentially eliminating lymphodepletion [11][25] Market Data and Key Metrics Changes - Nearly 50 activated US sites are involved in the ALPHA-three trial, with plans for international expansion starting in Canada [21] - The company is experiencing strong enthusiasm from investigators, which is translating into increased patient screening activity [20][21] Company Strategy and Development Direction - The company is focused on making CAR T therapies more accessible through an allogeneic approach, with a strategy launched in January 2024 aimed at redefining cell therapy [6][13] - The company is prioritizing cash runway preservation, extending it into the second half of 2027, while driving forward with promising clinical trials [12][28] - The company is adapting its operational strategy to address macroeconomic challenges and enhance trial execution [12][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the evolving regulatory landscape and expresses confidence in the FDA's commitment to scientific integrity and patient-centered outcomes [14][15] - The company believes that strong science and meaningful clinical benefits will continue to prevail in the regulatory environment [16] - Management is optimistic about the potential of their allogeneic CAR T programs to reshape treatment paradigms in hematologic malignancies and solid tumors [27] Other Important Information - The company is making targeted reductions in manufacturing operations to achieve cost savings while maintaining core capabilities [28] - The ALLO-three sixteen data will be presented at ASCO on June 1, which is expected to be significant for the field [22] Q&A Session Summary Question: Progress of enrollment in the first line study and logistical issues - Management explained that site-related issues caused a 3-4 month delay in patient screening, but recent improvements in site engagement are translating into increased screening activity [35][36] Question: Differences in site-related factors between community and academic sites - Management indicated that there is no significant difference in the occurrence of site-related factors between community and academic sites, with both showing encouraging activity once operational [40][46] Question: Regulatory implications of expanding to international sites - Management stated that the global standard for frontline DLBCL treatment remains consistent, and the expansion is not expected to introduce significant heterogeneity [65] Question: Potential partnership for autoimmune programs - Management expressed willingness to partner on autoimmune programs to de-risk them, especially given the current market environment [68] Question: Expected data size for ALLO-three 29 - Management indicated that the expected data size for the initial readout will be limited due to the nature of the dose escalation study, but they are focused on ensuring robust data collection [75] Question: Overlap of site-related challenges in ex-US sites - Management believes that ex-US sites will be better equipped due to the integrated care model typically found in those regions [96]